ASCO 2022 Conference Coverage


 

ASCO 2022 on a Randomized Phase II/III PARTNER Trial to Evaluate the Safety & Efficacy of the Addition of Olaparib to Platinum-Based Neoadjuvant Chemo in TNBC and/or Germline BRCAm BC

119 views
June 16, 2022
Comments 0
Login to view comments. Click here to Login